osimertinib for the t790m resistance mutation
Published 7 years ago • 1.1K plays • Length 5:29Download video MP4
Download video MP3
Similar videos
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
5:45
osimertinib in t790m-mutant lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
3:13
osimertinib responses after rociletinib treatment of t790m-positive nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
0:58
dr. camidge on inhibiting initial activating egfr mutations and the t790m resistance mutation
-
1:15
osimertinib improves survival in egfr nsclc, poses new challenges for resistance
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
3:45
azd9291 and rociletinib in t790m-mutant nsclc
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
5:52
mechanisms of osimertinib resistance in aura 3
-
6:06
osimertinib, the standard for egfr nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
1:41
dr. goldberg on resistance to osimertinib for nsclc